Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consistency, immunogenicity, and safety of three commercial-scale batches of 23-valent pneumococcal polysaccharide vaccine in adults aged 40–65
CTR20230345Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Feb 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Sinovac Biotech Ltd.. Started Feb 2023; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20230345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230345.